Infectious events in pediatric patients with acute lymphoblastic leukemia/lymphoma undergoing evaluation for fever without severe neutropenia
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34476
Abstract: Infections cause significant treatment‐related morbidity during pediatric acute lymphoblastic leukemia/lymphoma (ALL/LLy) therapy. Fevers during periods without severe neutropenia are common, but etiologies are not well‐described. This study sought to describe the bloodstream infection (BSI) and… read more here.
Keywords: leukemia lymphoma; severe neutropenia; without severe; lymphoblastic leukemia ... See more keywords
Prolonged severe neutropenia after the first daratumumab administration for multiple myeloma with baseline neutropenia
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Hematology"
DOI: 10.1007/s00277-019-03711-0
Abstract: Dear Editor, Daratumumab, an anti-CD38 monoclonal antibody, shows substantial efficacy for relapsed and refractory multiple myeloma (MM). Daratumumab also has a clinically manageable and acceptable safety profile. Grade 3–4 neutropenia was recorded in 5–12% of… read more here.
Keywords: treatment; severe neutropenia; therapy; neutropenia ... See more keywords
Incidence and non-genetic risk factors of irinotecan-induced severe neutropenia in Chinese adult inpatients
Sign Up to like & getrecommendations! Published in 2023 at "Medicine"
DOI: 10.1097/md.0000000000033005
Abstract: To analyze the incidence and nongenetic risk factors of irinotecan-induced severe neutropenia in the hospital, and provide additional reference and help for clinical treatment. A retrospective analysis of patients who received irinotecan based chemotherapy from… read more here.
Keywords: induced severe; severe neutropenia; risk factors; analysis ... See more keywords
GX-G3, a long-acting G-CSF, compared with pegfilgrastim in reducing duration of severe neutropenia after chemotherapy for non-Hodgkin’s lymphoma.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.e19065
Abstract: e19065 Background: G-CSF is used in patients at significant risk for developing severe neutropenia (neutrophil count < 0.5 × 109/L or grade 4 neutropenia) following myelosuppresive chemotherapy. GX-G3, human G-CSF fused to hyFc is a… read more here.
Keywords: duration severe; csf; severe neutropenia; chemotherapy ... See more keywords
Severe neutropenia: a prognosticator in patients with advanced/recurrent colorectal cancer under oral trifluridine-tipiracil (TAS-102) chemotherapy.
Sign Up to like & getrecommendations! Published in 2017 at "Die Pharmazie"
DOI: 10.1691/ph.2017.6808
Abstract: BACKGROUND/AIM The effect of oral trifluridine-tipiracil (TAS-102)-induced neutropenia on survival of patients with advanced/recurrent colorectal cancer was investigated. PATIENTS AND METHODS Between August 2014 and May 2016, 41 patients underwent TAS-102 monotherapy at Ogaki Municipal… read more here.
Keywords: colorectal cancer; severe neutropenia; tas 102; patients advanced ... See more keywords
Risk factors and efficacy outcomes of early-onset severe neutropenia due to paclitaxel or nanoparticle albumin-bound paclitaxel combined with ramucirumab in advanced gastric cancer: a multicenter retrospective cohort study
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Gastrointestinal Oncology"
DOI: 10.21037/jgo-22-499
Abstract: Background Paclitaxel or nanoparticle albumin-bound paclitaxel combined with ramucirumab (PTX/nab-PTX + RAM) is widely used as second-line chemotherapy for advanced gastric cancer (AGC), but severe neutropenia often develops with this regimen. Although previous studies have… read more here.
Keywords: ptx; severe neutropenia; risk factors; paclitaxel ... See more keywords
The clinical outcomes and biomarker features of severe sepsis/septic shock with severe neutropenia: a retrospective cohort study.
Sign Up to like & getrecommendations! Published in 2021 at "Translational pediatrics"
DOI: 10.21037/tp-20-230
Abstract: Background Severe sepsis/septic shock with severe neutropenia often leads to poor prognosis. However, it is unknown if severe neutropenia is associated with different clinical outcomes and biomarker features in severe sepsis/septic patients. Methods This retrospective… read more here.
Keywords: septic shock; sepsis septic; severe sepsis; severe neutropenia ... See more keywords
Severe Neutropenia is Associated with Better Clinical Outcomes in Patients with Advanced Pancreatic Cancer Who Receive Modified FOLFIRINOX Therapy
Sign Up to like & getrecommendations! Published in 2018 at "Cancers"
DOI: 10.3390/cancers10110454
Abstract: While modified FOLFIRINOX therapy is effective for treating advanced pancreatic cancer, it frequently causes severe neutropenia. The present study investigated the effect of severe neutropenia on clinical outcomes in advanced pancreatic cancer patients who received… read more here.
Keywords: folfirinox therapy; modified folfirinox; advanced pancreatic; severe neutropenia ... See more keywords
Implementing Pre-Therapeutic UGT1A1 Genotyping in Clinical Practice: A Real-Life Study
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Personalized Medicine"
DOI: 10.3390/jpm12020204
Abstract: Current guidelines recommend pre-therapeutic UGT1A1 genotyping to guide irinotecan dosing, but the usefulness of this approach remains to be clarified. In 247 patients with advanced gastrointestinal cancers undergoing irinotecan-based chemotherapy, we prospectively performed UGT1A1*28 genotyping… read more here.
Keywords: ugt1a1 genotyping; implementing pre; severe neutropenia; therapeutic ugt1a1 ... See more keywords
Concomitant administration of candesartan cilexetil in patients on paclitaxel and carboplatin combination therapy increases risk of severe neutropenia .
Sign Up to like & getrecommendations! Published in 2018 at "International journal of clinical pharmacology and therapeutics"
DOI: 10.5414/cp203180
Abstract: OBJECTIVE Angiotensin receptor blockers (ARBs) are often used in patients on paclitaxel (PTX) and carboplatin combination (TC) therapy to treat hypertension caused by the co-administration of bevacizumab. The aim of this retrospective study was to… read more here.
Keywords: therapy; combination therapy; candesartan cilexetil; severe neutropenia ... See more keywords